Prot #CBKM120ZUS40: Modular phase 2 study to link targeted therapy to patients with pathway activated tumors: Module 1 - BKM120 for patients with PI3K-activated tumors

Project: Research project

Project Details

StatusFinished
Effective start/end date5/21/1412/31/17

Funding

  • United BioSource LLC (Prot #BKM120)
  • Novartis Pharmaceuticals Corporation (Prot #BKM120)